Both Endocyte and Merck have much to gain from potential $1bn cancer alliance
This article was originally published in Clinica
Executive Summary
In a $1bn partnership for Endocyte's lead folate-targeting cancer drug candidate and its companion diagnostic, the West Lafayette, Indiana-based biopharmaceutical company gets money to advance more of its early stage programmes and Merck gets access to an oncology therapeutic that may have a better chance of winning regulatory approval than its competitors.
You may also be interested in...
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.
Pharma On The Hunt For Oncology Partners Across Modalities
The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.